MIRA Pharmaceuticals Q2 2026: Going Concern Doubt, Cash Runway to Q1 2027, Nasdaq Delisting Risk
MIRA sits 23% above its 52-week low of $0.6 on light trading volume (0.3× avg).
Summary
MIRA Pharmaceuticals' Q2 2026 report raises substantial doubt about its ability to continue as a going concern, with cash only expected to last into Q1 2027 and a Nasdaq delisting risk looming.
Key Events · Earnings and Guidance · MIRA
-
Going Concern Doubt
The company states it has insufficient cash to support operations for at least 12 months from the issuance date, raising substantial doubt about its ability to continue as a going concern.
-
Cash Runway to Q1 2027
Cash and cash equivalents were $3.6 million as of June 30, 2026, and management expects this to fund operations only into the first quarter of 2027.
-
Nasdaq Delisting Risk
The company received a Nasdaq deficiency letter on July 27, 2026, for trading below $1 for 30 consecutive business days. It has until January 25, 2027 to regain compliance, with a possible second 180-day period and reverse split option.
-
Financial Losses Continue
Net loss was $2.4 million for the six months ended June 30, 2026, with no revenue. Accumulated deficit reached $42 million.
Analysis · MIRA · Life Sciences
MIRA Pharmaceuticals' Q2 2026 10-Q reveals substantial doubt about its ability to continue as a going concern, with only $3.6 million in cash and a runway expected to last only into the first quarter of 2027. The company also disclosed details of a Nasdaq deficiency letter received on July 27, 2026, giving it until January 25, 2027 to regain compliance with the $1 minimum bid price requirement. While the Nasdaq deficiency was previously disclosed in an 8-K, this filing adds the critical going concern language and cash runway estimate, which are new material facts. The company has no revenue, a net loss of $2.4 million for the first half of 2026, and an accumulated deficit of $42 million. Management states it will need to raise additional capital, but there is no assurance it can do so on acceptable terms. This is a high-risk situation for investors.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIRA was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31M. The 52-week trading range was $0.60 to $2.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.